Editorial Board

Editor-in-Chief

  1. Professor, Laboratory Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands

Editorial Board Member

  1. Professor, Fred Wyszkowski Cancer Research Laboratory, Technion - Israel Institute of Technology, Haifa, Israel
  2. President of the Oncoclinical Institute and Director of the Oncoclinica Group, Rio de Janeiro, Brazil
  3. Associate Professor, Lab Medical Oncology, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, The Netherlands; Cancer Pharmacology Lab, AIRC Start-Up Unit, University of Pisa, Pisa, Italy
  4. Professor, Department of Biomedical Sciences, Faculty of Medicine, University of Namur, Namur, Belgium
  5. Professor, Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, United States
  6. Cancer Biology Laboratory, Lutheran University of Brazil, Canoas, Brazil
  7. Professor, Clinical Pharmacy Group, Department of Pharmaceutical and Medical Chemistry, University of Münster, Münster, Germany
  8. Department of Rheumatology, Amsterdam Rheumatology and immunology Center (ARC), Cancer Center Amsterdam, VU University Medical Center, Amsterdam, The Netherlands
  9. Division of Medical Oncology, University of Basel, Basel, Switzerland
  10. Institute of Pharmacy, University of Bonn, Bonn, Germany
  11. Professor, Faculty of Health Sciences, University of Macau, Macau, China
  12. Department of Health Sciences, University of Florence, Florence, Italy
  13. Division of Medicine, Roswell Park Cancer Institute, Buffalo, NY, United States
  14. Professor, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, United States
  15. Professor, School of Biosciences, University of Kent, Canterbury, UK.
  16. Molecular Pharmacology, School of Pharmaceutical Sciences (EPGL), University of Geneva, Geneva, Switzerland
  17. Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy
  18. Professor, School of Pharmacy, University of Huddersfield, Huddersfield, United Kingdom
  19. Professor, Department of Genetics, Physical Anthropology and Animal Physiology (School of Medicine) of the University of the Basque Country (UPV/EHU), Basque Country, Spain
  20. Nova Medical School (NMS), Universidade Nova de Lisboa/Faculty of Medical Sciences, New University of Lisbon, Lisbon, Portugal
  21. Professor, Division of Pharmaceutics & Pharmaceutical Chemistry College of Pharmacy, The Ohio State University, Columbus, OH, United States
  22. Professor, Translational Oncology of Solid Tumors, Experimental and Clinical Research Center, Charité – Universitätsmedizin und Max-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany
  23. Executive Medical Director, Global Oncology and Hematology, Syneos Health. President, Ares Pharmaceuticals, White Bear Lake, MN, USA
  24. Professor, Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
  25. Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, United States
  26. Professor, Department of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
  27. Molecular Pharmacology Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Cancer Drug Resistance ISSN 2578-532X (Online)
Partners
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.